The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects

Cassinelli, Giuliana; Zuco, Valentina; Petrangolini, Giovanna; Cesare, Michelandrea De; Tortoreto, Monica; Lanzi, Cinzia; Cominetti, Denis; Zaffaroni, Nadia; Orlandi, Augusto; Passeri, Daniela; Meco, Daniela; Francesco, Angela Maria Di; Riccardi, Riccardo; Bucci, Federica; Pisano, Claudio; Zunino, Franco

doi:10.1016/j.bcp.2012.04.005

Cited by 27 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Formalin-fixed, decalcified, paraffin-embedded femoral head samples were cut in 5 µm-thick serial sections, stained with Haematoxylin & Eosin and examined by light microscopy (Cassinelli et al 2012). Articular cartilage and OA changes were evaluated according to international criteria (Collins and McElligotte 1960;Orlandi et al 2009).…”

Section: Histological and Histomorphometric Evaluationmentioning

confidence: 99%

Comparison of tissue transglutaminase 2 and bone biological markers osteocalcin, osteopontin and sclerostin expression in human osteoporosis and osteoarthritis

et al. 2016

Self Cite

View full text Add to dashboard Cite

Osteoporosis (OP) and osteoarthritis (OA) are the most common joint diseases, with a high incidence in the elderly population. OP is characterized by trabecular bone remodeling and reabsorption, whereas articular cartilage and subchondral bone remodeling are major features of OA. Although classically considered as independent or even conflicting processes, clinical coexistence of OP and OA was recently described. Transglutaminase 2 (TG2) expression is considered a biomarker of OA, but its role in osteoporotic bone remodeling is still uncertain. We investigated TG2 and bone biological markers (Osteocalcin, Osteopontin, and Sclerostin) in osteoporotic and osteoarthritic osteocartilagineous tissue (n = 54) and human chondrocyte cultures in vitro by immunohistochemistry, immunofluorescence and RT-PCR. Histomorphometric evaluation of bone trabecular remodeling was also performed. In cartilage, TG2 expression was faint in control and OP and significantly less than in OA and OP + OA chondrocytes; the opposite was found for Osteocalcin, whereas Osteopontin and Sclerostin expression was similar. In the subchondral trabecular bone, osteocytes/osteoblasts TG2 expression was slight and similar comparing control, OP, OA, and OP + OA group, whereas Osteocalcin and Osteopontin expression was lower in OP compared to control, OA and OP + OA. Increased TG2 and reduced Osteocalcin expression were maintained in human osteoarthritic chondrocytes in vitro. Histomorphometric analysis confirmed reduced trabecular bone mass in OP and OP + OA compared with OA patients. TG2 represented a suitable biomarker of osteoarthritic chondrocyte activation, whereas osteocalcin and osteopontin characterized osteoporotic osteocyte/osteoblast changes; differences were lost in OP + OA patients, suggesting careful consideration when coexistence of the two diseases occurs.

show abstract

Section: Histological and Histomorphometric Evaluationmentioning

confidence: 99%

Comparison of tissue transglutaminase 2 and bone biological markers osteocalcin, osteopontin and sclerostin expression in human osteoporosis and osteoarthritis

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Tumor microenvironment consists in a complex signaling network which influences the behavior of both resident stem cells and tumor cells [15]. Angiogenesis is one of the crucial events for cancer development and growth, and VEGF secretion plays a pivotal role in this process, thereby becoming a main target for antitumor strategies [16,17]. ASCs may contribute to stromal support for cancer cells by the local delivering of inflammatory cytokines and/or growth factors including VEGF, thus facilitating the recruitment of migratory cancer cells, tumor growth and metastasis [18].…”

Section: Adipose Derived Stem Cells and Breast Cancer Progressionmentioning

confidence: 99%

Adipose Tissue-Derived Stem Cell Therapy for Post-Surgical Breast Reconstruction - More Light than Shadows

Bielli¹,

Gentile²,

Cervelli³

et al. 2015

Adv Clin Exp Med

Self Cite

View full text Add to dashboard Cite

Breast cancer remains the most common tumor in women, and new techniques for post-surgical breast reconstruction have been recently introduced. These new procedures include autologous fat grafting with or without the enrichment with autologous stromal vascular fraction (SVF), platelet-derived growth factors and insulin. The reported improvement of fat graft viability with these techniques likely depends on the presence in the SVF of multipotent resident adipose derived-stem cells (ASCs). The clinical advantage derives from the plasticity of ASCs and their ability to generate new functional adipose tissue and vessels. However, there is an ongoing debate regarding the possible interplay between breast tumor cells and resident or transplanted ASCs for their capacity to locally secrete growth factors. Most of the data in the literature concerning ASCs is derived from in vitro models, whereas the knowledge of ASC behavior in vivo remains scarce. Recent reports concerning SVF/ASC enrichment of fat graft did not describe any significant worsening of prognosis for patients undergoing those procedures. However, further studies and longer follow-ups are needed to specifically define technical procedures and to confirm the safety of procedures of SVF/ASC enrichment during post-surgical breast reconstruction (Adv Clin Exp Med 2015, 24, 3, 545-548).

show abstract

“…In Evan's LGFMS series, one case displayed anaplastic dedifferentiation at 30-years follow-up [5]. The presence of a rich and delicate vascularization of LGFMS suggests a potential target for additional postsurgical therapy [6]. The most interesting features of this case are the first description of the cardiac location of an LGFMS, usually occurring in the lower limbs, and the progression after 7 years to a high-grade sarcoma.…”

Section: Commentsmentioning

confidence: 79%

Low-grade fibromyxoid sarcoma: an unusual cardiac location

Ferlosio

Doldo

Polisca

et al. 2013

Cardiovascular Pathology

Self Cite

View full text Add to dashboard Cite

We report the unusual cardiac localization of a primary low-grade fibromyxoid sarcoma of the right ventricle in a 57-year-old woman. Histological examination revealed a prevalent myxoid appearance with whorling growth pattern of small or spindle cells with bland features alternating with rare more collagenous hypocellular areas with rare atypical cells. Genomic polymerase chain reaction of genomic DNA revealed the typical FUS/Creb3L2 fusion gene products typical of low-grade fibromyxoid sarcoma. The tumor was surgically removed and recurred after 7 years as high-grade pleomorphic sarcoma. The patient died 6 months after the clinical manifestation of recurrence. Low-grade fibromyxoid sarcoma of soft tissues is a rare, distinctive variant of fibrosarcoma-typically arising in deep soft tissue of lower extremities and trunk-that rarely metastasizes. Clinically, low-grade fibromyxoid sarcoma is characterized by a longer survival rate compared to other sarcomas, suggesting its consideration in the differential diagnosis of cardiac tumors with a myxoid appearance.

show abstract

The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects

Cited by 27 publications

References 27 publications

Comparison of tissue transglutaminase 2 and bone biological markers osteocalcin, osteopontin and sclerostin expression in human osteoporosis and osteoarthritis

Comparison of tissue transglutaminase 2 and bone biological markers osteocalcin, osteopontin and sclerostin expression in human osteoporosis and osteoarthritis

Adipose Tissue-Derived Stem Cell Therapy for Post-Surgical Breast Reconstruction - More Light than Shadows

Low-grade fibromyxoid sarcoma: an unusual cardiac location

Contact Info

Product

Resources

About